文献速递呼吸道感染呼吸危重症与机械通气

三聚体IgM在临床前肺炎模型中支持抗菌防御并限制炎症

Trimodulin supports antibacterial defence and restricts inflammation in preclinical pneumonia models.
PubMed 文献 · Eur Respir J · 2026-02-05

该研究在小鼠肺损伤与感染诱导的非无菌性炎症模型中评估三聚体IgM(trimodulin)的保护作用。结果显示trimodulin通过调理吞噬减少细菌负荷并独立抑制炎症,保留肺泡屏障完整性并减少肺水肿,与氨苄西林联用增强抗炎效果。提示其可能为重症社区获得性肺炎的潜在疗法。

要点

  • trimodulin通过调理吞噬增强抗菌防御并独立抑制炎症。
  • trimodulin减少细菌负荷、疾病严重度并保留肺泡屏障。
  • trimodulin与氨苄西林联用增强炎症抑制。

核心结论

  • 临床前肺炎模型提示trimodulin可能成为重症社区获得性肺炎的有前景疗法。

研究设计与样本

  • 研究采用小鼠肺损伤模型,包括呼吸机诱导肺损伤和感染诱导的非无菌性炎症模型。

主要发现

  • trimodulin显著保护小鼠免受致死性肺炎链球菌肺炎,降低细菌负荷和疾病严重度。
  • trimodulin保留肺泡屏障完整性并限制肺水肿。
  • trimodulin的抗菌作用通过调理吞噬介导,抗炎作用独立于该机制。
  • trimodulin与氨苄西林联用增强炎症抑制。

临床怎么用

  • 在重症社区获得性肺炎高C反应蛋白和低IgM水平患者中,trimodulin可能增强宿主防御并限制肺部炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe community-acquired pneumonia remains a global health challenge with high mortality despite advances in antibiotic therapy and supportive care. Immunoglobulin therapies, especially IgM-containing ones, have shown promise in enhancing host defence and reducing inflammation. The CIGMA trial highlighted the potential of trimodulin to lower mortality in patients with severe community-acquired pneumonia with high C-reactive protein and low IgM levels. METHODS: We investigated the protective effects of trimodulin on clinical status, bacterial burden, lung integrity and inflammatory responses in murine models of lung injury, including both ventilator-induced lung injury and infection-induced models with nonsterile inflammation. RESULTS: In mice, trimodulin significantly protected against lethal pneumococcal pneumonia by reducing bacterial burden and disease severity while preserving alveolar barrier integrity and limiting lung oedema. The antibacterial action of trimodulin was mediated through opsonophagocytosis, and its anti-inflammatory effects operated independently of the latter. When combined with ampicillin, trimodulin exhibited enhanced suppression of inflammation. CONCLUSION: Our findings in preclinical pneumonia models suggest that trimodulin could be a promising therapy for severe community-acquired pneumonia. We provide evidence that trimodulin enhances host defence, reduces detrimental pulmonary inflammation and barrier dysfunction, and limits pulmonary oedema, which may explain the beneficial effects observed in patients with severe community-acquired pneumonia.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Nouailles, Bischoff, Linke, et al. Trimodulin supports antibacterial defence and restricts inflammation in preclinical pneumonia models. Eur Respir J. 2026. PMID: 40935582. doi:10.1183/13993003.00392-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。